REVELATION BIOSCIENCES INC
REVBNASDAQπ #5133 by market capEarnings Feb 24 Β· PostUS Equity
$3.77βΌ $0.61 (β13.93%)
Market closed Β· at closeTrack REVB
Get earnings, price moves & breaking news on Telegram
24hβΌ 13.9%
7dβΌ 13.9%
14dβΌ 2.3%
30dβ² 0.1%
ytdβΌ 83.1%
1yβΌ 84.1%
π¦Market Cap
$3M
Small Cap
πRevenue Growth (YoY)
β
πGross Margin
β
π΅FCF Margin
β
βοΈP/S Ratio
β
Otter Score
β
Insufficient data
Trading Snapshot
- Day Range
- $3.77 β $3.77
- 52-Week Range
- $3.08 β $40.60
- Volume (shares)
- 102
- Avg Volume (shares)
- β
- Shares Outstanding
- 680,000
- Next Earnings
- 2027-02-24
Fundamentals Snapshot
- Annual Revenue
- β
- Last Q Revenue
- β
- P/E Ratio
- β
- P/S Ratio
- β
- EPS (TTM)
- $-26.98
- Dividend Yield
- β
- Dilution (1yr)
- +79.2%
REVELATION BIOSCIENCES INC
REVBFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isnβt profitable yet.
β$9Mβ² +13.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
β$8MβΌ β54.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing ownerβs slice.
89Kβ² +79.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$10Mβ² +$3M YoY
About REVELATION BIOSCIENCES INC
Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system. The company's therapeutic pipeline includes promising candidates such as GEM-AKI, which is being developed as a potential therapy for both the prevention and management of acute kidney injury, and GEM-CKD, intended for the prevention and treatment of chronic kidney disease. Established in 2019, this San Diego, California-based enterprise was formerly known as Petra Acquisition, Inc., before officially adopting the name Revelation Biosciences, Inc. in January 2022.
π¦¦
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
π§Dilutionβ
β
β
β
β
Overall Score
Insufficient data
β/100
Analyst Ratings
βConsensus
Buy
7 analysts
Strong Buy2
Buy4
Hold1
Sell0
Strong Sell0
Ratings as of Nov 2026
Latest News & Updates
News unavailable.